



Methodological note for HCP/ORDM/HCO/PO/MoP disclosure 2025

Version: 1.0, 31.03.2026
Country: UK and Ireland
Data year: 2025
Year of publication: 2026

Dr Falk Pharma UK Ltd is committed to the promotion of research, scientific exchange and the development of medicines. We promote shared learning between communities of patients, clinicians and researchers. The shared knowledge helps Dr Falk to develop treatment options that work for our patients and lead to successful disease treatment.

In the pursuit of shared learning, Falk Foundation has been established in the UK & Ireland in 2025 as our scientific and educational excellence partner. The Falk Foundation is focused on offering independent medical education through events, comprehensive range of resources and recognition of achievements in the fields of gastroenterology and hepatology, as well as supporting the work of patient organisations.

The relationship between the pharmaceutical industry and health professionals (HCPs) and healthcare organisations (HCOs) is vital for the development and delivery of life-enhancing and life-saving medicines. All collaborators want to ensure that patients and others have confidence that the relationship between pharmaceutical companies and the doctors, nurses, pharmacists and other health professionals and organisations is open and transparent.

Dr Falk Pharma UK Ltd discloses details of payments and other benefits in kind made to HCPs and HCOs. UK information is published on a database called Disclosure UK and Ireland data on the website at drfalkpharma.co.uk. Transfers of value to support non HCPs and HCO's, such as members of the public and patient organisations are subject to separate disclosure and can be found on our website.

The methodological notes below explain the data Dr Falk Pharma UK Limited disclose and how the data is prepared.

Contents

1	Definitions.....	3
1.1	Recipients.....	3
1.2	Kind of ToVs.....	3
2	Disclosure's Scope.....	4
2.1	Products concerned.....	4
2.2	Company concerned.....	4
2.3	Excluded ToVs.....	4
2.4	ToVs date.....	4
2.5	Direct ToVs.....	4
2.6	Indirect ToVs.....	5
2.7	Non-monetary ToVs.....	5
2.8	ToVs in case of partial attendances or cancellation and refund.....	5
2.9	Cross-border activities.....	5
2.10	R&D.....	5
2.11	Voluntary disclosure.....	5
3	Specific considerations.....	5
3.1	Country unique identifier.....	5
3.2	Self-incorporated HCP.....	5
3.3	Multi-year agreements.....	5
3.4	Country specificities.....	5
3.5	Quality Checks.....	6
4	Data protection legal basis.....	6
4.1	Consent collection.....	6
4.2	Legitimate interests.....	6
5	Form of disclosure.....	6
5.1	Date of publication.....	6
5.2	Disclosure platform.....	6
5.3	Disclosure language.....	6
6	Disclosure financial data.....	6
6.1	Currency.....	6
6.2	VAT included or excluded.....	6
6.3	Calculation rules.....	6
7	Additional Information.....	6

1 Definitions

1.1 Recipients

All recipients of transfers of value will be included. These include health professionals, healthcare organisations, members of the public and patient organisations.

Health professionals (HCPs) include doctors, nurses, pharmacists, radiologists etc. who work within our field of medicine and in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine. In some cases, retired health professionals receive a transfer of value where they continue to provide services in scope of the Code (e.g. consultancy, speaking). Since the purpose of engagement is to influence prescribing, Dr Falk will include those data in the disclosure.

Health care organisation (HCOs) includes healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in the UK.

Members of the public (MOPs), such as scientific researchers or patients may be asked to speak at one of our educational meetings.

Patient organisations (PO's) are providers of essential support and information to those living with medical conditions, as well as their families and carers. Working with these valued organisations allows Dr Falk Pharma UK Ltd to support their efforts with vital resources.

1.2 Kind of ToVs

The data disclosed by Dr Falk Pharma UK Limited is consistent with the requirements of the current **ABPI and IHPA Codes of Practice**.

Support of health professionals to attend educational events

The data includes all travel costs and accommodation costs but does not include food and drink costs. The data also includes the registration fee, where applicable, for the health professional to be registered to attend the educational event. These events could be 3rd party organised congress / conferences or Dr Falk Pharma organised events.

Payment of consultants who provide services to Dr Falk Pharma UK Ltd

The data includes payments to health professionals who provide services to Dr Falk Pharma UK Ltd (fees). Where applicable, the data also includes payment of expenses to consultants in the delivery of their services, such as travel expenses or accommodation expenses, in line with the current Codes of Practice.

Donations, grants and benefits to health care organisations & patient groups

The data includes transfers of value to health care organisations. The provision of equipment or materials by Dr Falk Pharma UK Limited for specific projects and / or any time spent in lieu of funding is calculated and the value assigned as a donation.

Funding towards a purpose of which Falk have no input or influence, and receive no benefit is a grant. Support is declared where appropriate.

Sponsorship

The data includes transfers of value to health care organisations such as the provision of meeting organisation services by Dr Falk Pharma UK Limited or payment to support educational meetings or projects that enhance patient care or benefit the NHS and maintain patient care. Support is declared on materials relating to the specific event or programme.

Collaborative working

Dr Falk Pharma has not undertaken any collaborative projects during 2025.

2 Disclosure's Scope

2.1 Products concerned

Dr Falk Pharma UK Ltd are suppliers of prescription only medicines and this disclosure covers only those products.

2.2 Company concerned

This methodological statement and disclosure relates only to Dr Falk Pharma UK Ltd and the TOVs transferred to UK and Ireland recipients by other Dr Falk Pharma affiliates.

2.3 Excluded ToVs

As per the current Codes of Practice – the following TOVs are excluded from disclosure

Subsistence when a HCP is supported as an attendee or as a consultant at one of our events.

Pens / notepads provided as part of our meeting are also excluded from disclosure

In addition, where service providers such as travel companies etc have charged Dr Falk a fee for their services, these have not been included in the TOV.

2.4 ToVs date

There is an inevitable delay between the date of agreement and the date on which the payment is made. Dr Falk Pharma UK Ltd. will disclose the date the payment was made and not the date the activity was conducted.

2.5 Direct ToVs

Direct TOVs are made directly by Dr Falk for the benefit of the recipient e.g.

Event support - sponsorship of a HCP to attend a Dr Falk or 3rd party meeting. Travel support and registration are declared separately.

Service and Consultancy a HCP provides consulting services, based on scientific/medical expertise, reputation, knowledge and experience in a particular therapeutic area. Examples of the service includes chairing and presenting at meetings, product training, advisory board participation, review/input on publications, and product input. Participation in consultancy agreements requires an investment of time and expertise, therefore it is appropriate that they are paid for the time and reimbursed for expenses such as travel. Fees and expenses are disclosed separately

Grant and Donations are payments made to a health care organisation for an educational scientific or charitable purpose.

2.6 Indirect ToVs

Indirect TOVs are made on behalf of Dr Falk for the benefit of a recipient or through an intermediate (e.g. medical education agencies, event organisers) and where the company knows or can identify the recipient that will benefit.

Payments to charity and HCO as fees - On occasion, a HCP who has provided a service to Dr Falk Pharma UK Ltd may ask for their fee to be paid to charity or to the HCO where they are employed. On these occasions, or similar, the fee received by the HCP will be disclosed under that HCP's entry.

2.7 Non-monetary ToVs

No non-monetary ToVs such as staff time, loaned equipment, or other in-kind benefits were provided in 2025

2.8 ToVs in case of partial attendances or cancellation and refund

In the case where Dr Falk has been unable to obtain a refund when the recipient of the TOV has been unable to attend / participate; Dr Falk will disclose that individual TOV.

2.9 Cross-border activities

Dr Falk Pharma UK Ltd operates in both the UK and Ireland. All payments made by Dr Falk Pharma UK Ltd in the UK or Ireland are declared. UK disclosures appear on the ABPI database, and disclosures in Ireland are available on our website.

Where Dr Falk GmbH have made transfers of value to UK recipients, values have been aggregated .

Where non UK / Ireland HCPs and members of the public have been paid for a service, where appropriate, their details have been passed to our Dr Falk colleagues worldwide for disclosure in the relevant territory.

2.10 R&D

There are no R&D transactions for 2025.

2.11 Voluntary disclosure

Dr Falk Pharma UK Ltd meets the disclosure requirements of the codes of practice for UK and IE.

3 Specific considerations

3.1 Country unique identifier

Dr Falk use proprietary HCP / HCO identifiers.

3.2 Self-incorporated HCP

Where TOVs have been paid to HCPs via their limited company, the TOV has been disclosed against that HCP.

3.3 Multi-year agreements

There are no multi-year contracts including 2025.

3.4 Country specificities

N/A

3.5 Quality Checks

All TOVs are matched to outgoing account payments prior to disclosure. All recipients of TOVs in Ireland were contacted with disclosure details prior to publishing.

4 Data protection legal basis

4.1 Consent collection

N/A

4.2 Legitimate interests

Following a Legitimate Interests Assessment and appropriate notifications, Dr Falk Pharma UK moved to legitimate interests as the legal basis for processing disclosure payments in 2022. Individuals rights are protected by their ability to raise objections by contacting privacy@drfalkpharma.co.uk.

5 Form of disclosure

5.1 Date of publication

30 June 2026

5.2 Disclosure platform

UK – HCPs / HCOs - Disclosure UK www.disclosureuk.org.uk

PO / MOPs - [Dr Falk website](#)

Ireland HCPs /HCOs - [Dr Falk website](#)

5.3 Disclosure language

English

6 Disclosure financial data

6.1 Currency

GBP. Disclosures are made in pounds sterling (£). Where the original payment was made in another currency, the value was converted to pounds at the exchange rate prevailing at the time of the payment.

6.2 VAT included or excluded

The value reported is the total amount paid by Dr Falk, including VAT where applicable.

6.3 Calculation rules

All TOVs in 2025 have been absolute values, no non-monetary values are included.

7 Additional Information

N/A